Regeneus (ASX: RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of Leo Lee as an independent non-executive director of Regeneus with effect from December.
Leo is a senior executive with over 20 years of experience in pharmaceutical innovation, commercialization, regulation and policy development. He has worked in North America and Asia and has spent the last 12 years living and working in Japan. Leo is President of Merck Serono, Japan and was previously the President of Allergan, Japan.
Regeneus Chairman, Dr Roger Aston said: “On behalf of the Directors, I welcome Leo to the Regeneus Board. Leo brings a wealth of pharmaceutical business experience gained from his senior leadership roles in Allergan and Merck Serono. His skills, experience, network and knowledge of the Japanese market make him a valuable and strategic addition to the Board particularly with our recent collaboration with AGC in Japan and our focus on clinical licensing and development of Progenza for the Japanese regenerative medicine market”.